FDA Approves PENTAZOCINE AND NALOXONE — Actavis Pharma, Inc.

Actavis Pharma has received approval for the Abbreviated New Drug Application (ANDA #074736) to market Pentazocine Hydrochloride, a generic oral formulation of the compound originally approved in 1997. The expanded distribution is expected to bolster Actavis's market presence in the opioid analgesic sector, providing a cost-effective alternative to the brand-name product.